Kamada jumps on inhaled Antitrypsin speculation

Kamada (KMDA +1.5%) rises as investors anticipate results from a European trial of an inhaled version of Antitrypsin, an AAT treatment. See profile on KMDA's website.

The Phase II/III study is scheduled to be completed by year-end.

Here's Jefferies Raj Denhoy (as quoted by Bloomberg): “If the trial is successful, and I think there is a pretty good chance for it to be a success, Kamada will have the only inhalable version of the drug on the market."

Jefferies estimate: $800M/year globally.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs